Using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis
Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, discusses the importance of developing definitions for risk stratification upon diagnosis in multiple myeloma. Dr Corre notes that the most effective tool currently available for risk stratification is measurable residual disease (MRD), however this cannot be implemented until after treatment. Dr Corre explains that molecular abnormalities represent a robust prognostic tool from the point of diagnosis, but the definitions of molecular high-risk vary globally. Dr Corre further notes that the International Myeloma Society (IMS) will soon work to generate a common definition of high-risk, and concludes with a list of molecular abnormalities that she considers high-risk. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found